|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYP4A11 |
Gene summary for CYP4A11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYP4A11 | Gene ID | 1579 |
| Gene name | cytochrome P450 family 4 subfamily A member 11 | |
| Gene Alias | CP4Y | |
| Cytomap | 1p33 | |
| Gene Type | protein-coding | GO ID | GO:0001655 | UniProtAcc | Q02928 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1579 | CYP4A11 | NAFLD1 | Human | Liver | NAFLD | 4.58e-11 | 7.14e-01 | -0.04 |
| 1579 | CYP4A11 | S43 | Human | Liver | Cirrhotic | 3.77e-08 | 1.89e-01 | -0.0187 |
| 1579 | CYP4A11 | HCC1_Meng | Human | Liver | HCC | 2.26e-24 | -6.43e-02 | 0.0246 |
| 1579 | CYP4A11 | HCC2_Meng | Human | Liver | HCC | 1.08e-07 | -1.54e-01 | 0.0107 |
| 1579 | CYP4A11 | S016 | Human | Liver | HCC | 1.56e-02 | -1.57e-01 | 0.2243 |
| 1579 | CYP4A11 | S029 | Human | Liver | HCC | 2.57e-06 | 1.04e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00463953 | Liver | NAFLD | carboxylic acid catabolic process | 73/1882 | 236/18723 | 4.16e-19 | 1.22e-15 | 73 |
| GO:00160544 | Liver | NAFLD | organic acid catabolic process | 73/1882 | 240/18723 | 1.20e-18 | 2.34e-15 | 73 |
| GO:00442825 | Liver | NAFLD | small molecule catabolic process | 91/1882 | 376/18723 | 8.96e-16 | 1.31e-12 | 91 |
| GO:00066316 | Liver | NAFLD | fatty acid metabolic process | 92/1882 | 390/18723 | 3.38e-15 | 3.29e-12 | 92 |
| GO:00160535 | Liver | NAFLD | organic acid biosynthetic process | 77/1882 | 316/18723 | 1.03e-13 | 6.69e-11 | 77 |
| GO:00463945 | Liver | NAFLD | carboxylic acid biosynthetic process | 75/1882 | 314/18723 | 6.37e-13 | 3.39e-10 | 75 |
| GO:00723295 | Liver | NAFLD | monocarboxylic acid catabolic process | 39/1882 | 122/18723 | 2.40e-11 | 8.77e-09 | 39 |
| GO:00160426 | Liver | NAFLD | lipid catabolic process | 63/1882 | 320/18723 | 1.35e-07 | 1.02e-05 | 63 |
| GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
| GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
| GO:1905952 | Liver | NAFLD | regulation of lipid localization | 34/1882 | 181/18723 | 2.51e-04 | 4.12e-03 | 34 |
| GO:00508787 | Liver | NAFLD | regulation of body fluid levels | 60/1882 | 379/18723 | 2.61e-04 | 4.23e-03 | 60 |
| GO:00335596 | Liver | NAFLD | unsaturated fatty acid metabolic process | 24/1882 | 116/18723 | 4.64e-04 | 6.74e-03 | 24 |
| GO:1905954 | Liver | NAFLD | positive regulation of lipid localization | 23/1882 | 110/18723 | 5.16e-04 | 7.15e-03 | 23 |
| GO:00016763 | Liver | NAFLD | long-chain fatty acid metabolic process | 23/1882 | 112/18723 | 6.73e-04 | 8.66e-03 | 23 |
| GO:0032368 | Liver | NAFLD | regulation of lipid transport | 28/1882 | 149/18723 | 8.39e-04 | 1.03e-02 | 28 |
| GO:01202545 | Liver | NAFLD | olefinic compound metabolic process | 28/1882 | 153/18723 | 1.28e-03 | 1.45e-02 | 28 |
| GO:0032370 | Liver | NAFLD | positive regulation of lipid transport | 18/1882 | 84/18723 | 1.49e-03 | 1.64e-02 | 18 |
| GO:00066906 | Liver | NAFLD | icosanoid metabolic process | 22/1882 | 123/18723 | 5.33e-03 | 4.11e-02 | 22 |
| GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYP4A11 | SNV | Missense_Mutation | c.643N>G | p.Gln215Glu | p.Q215E | Q02928 | protein_coding | tolerated(0.33) | benign(0.026) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CYP4A11 | SNV | Missense_Mutation | rs199678286 | c.1304N>A | p.Arg435His | p.R435H | Q02928 | protein_coding | deleterious(0.02) | possibly_damaging(0.898) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYP4A11 | SNV | Missense_Mutation | c.1472N>C | p.Ile491Thr | p.I491T | Q02928 | protein_coding | tolerated(0.17) | benign(0.007) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| CYP4A11 | SNV | Missense_Mutation | rs201985706 | c.842N>G | p.Glu281Gly | p.E281G | Q02928 | protein_coding | tolerated(0.13) | benign(0.097) | TCGA-LL-A441-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CYP4A11 | SNV | Missense_Mutation | novel | c.422N>G | p.Gln141Arg | p.Q141R | Q02928 | protein_coding | tolerated(0.18) | benign(0.443) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CYP4A11 | SNV | Missense_Mutation | novel | c.639T>G | p.Asn213Lys | p.N213K | Q02928 | protein_coding | tolerated(0.37) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CYP4A11 | SNV | Missense_Mutation | c.22N>A | p.Pro8Thr | p.P8T | Q02928 | protein_coding | tolerated(0.36) | benign(0.015) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| CYP4A11 | SNV | Missense_Mutation | rs556756716 | c.1336G>A | p.Ala446Thr | p.A446T | Q02928 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CYP4A11 | SNV | Missense_Mutation | novel | c.1180A>G | p.Ser394Gly | p.S394G | Q02928 | protein_coding | deleterious(0.01) | possibly_damaging(0.7) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CYP4A11 | SNV | Missense_Mutation | novel | c.1315N>A | p.Gly439Ser | p.G439S | Q02928 | protein_coding | tolerated(0.39) | benign(0.023) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1579 | CYP4A11 | ENZYME, CYTOCHROME P450, DRUGGABLE GENOME | amiloride | AMILORIDE | ||
| 1579 | CYP4A11 | ENZYME, CYTOCHROME P450, DRUGGABLE GENOME | spironolactone | SPIRONOLACTONE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |